Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells

Samuel V. Mussi,Rupa R. Sawant,Federico Perche,Mônica Cristina de Oliveira,Ricardo Bentes Azevedo,Lucas Antônio Miranda Ferreira,Vladimir P. Torchilin

Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells

2014

Samuel V. Mussi
Rupa R. Sawant
Federico Perche
Mônica Cristina de Oliveira
Ricardo Bentes Azevedo
Lucas Antônio Miranda Ferreira
Vladimir P. Torchilin

Purpose To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line.

Keywords:

Drug resistance
Doxorubicin
Docosahexaenoic acid
Biochemistry
Chemistry
cancer cell lines
In vitro
cancer therapy
pharmacology toxicology
mcf 7 adr
Pharmacology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations